API
< Back to all clusters
[BUSINESS] · United States · 11 sources

started · updated

Johnson & Johnson proposes $5.5 billion settlement to end talc cancer lawsuits

Johnson & Johnson has offered a voluntary settlement of roughly $5.5 billion to resolve about 76,000 ovarian‑cancer claims linked to its talc‑based baby‑powder and other products. The agreement covers existing lawsuits filed in a federal court in New Jersey and related state‑court actions across the United States. It will become effective only if at least 95 % of eligible claimants accept the terms. The company plans an initial payment of $3 billion in 2027, with the balance to be paid in 2028, though the total could rise if more claimants join. The settlement is negotiated outside bankruptcy court and does not extend to future talc‑related claims. Johnson & Johnson continues to assert that its talc products are safe, asbestos‑free, and not causally linked to cancer, despite previous attempts to resolve the litigation through bankruptcy that were rejected by U.S. courts.

Entities

American plaintiffs · Chris Seeger · Erik Haas · Johnson & Johnson · New Jersey · Ovarian cancer claimants · Talc litigation · U.S. District Court for the District of New Jersey · U.S. bankruptcy courts · US federal courts · United States federal courts · ovarian cancer

Claims

What the coverage asserts, and how many sources carry each claim.